Doptelet (avatrombopag)
Chronic Immune Thrombocytopenia (ITP)
Marketed / Phase 4Active
Key Facts
Indication
Chronic Immune Thrombocytopenia (ITP)
Phase
Marketed / Phase 4
Status
Active
Company
About Swedish Orphan Biovitrum
Sobi is a premier rare disease company with a mission to pioneer and deliver life-changing therapies for underserved patient populations. The company has established a strong commercial foundation with marketed products in hematology and immunology, complemented by a diversified pipeline of biologics and small molecules. Its strategy hinges on expanding global access, advancing high-potential clinical programs, and maintaining operational excellence to drive sustainable growth and leadership in the rare disease space.
View full company profileTherapeutic Areas
Other Chronic Immune Thrombocytopenia (ITP) Drugs
| Drug | Company | Phase |
|---|---|---|
| Fostamatinib (TAVALISSE) | Nippon Shinyaku | Approved |
| Fostamatinib (TAK-079 / MND-379) | Mochida Pharmaceutical | Launched |
| TAVALISSE (fostamatinib) | Rigel Pharmaceuticals | Marketed |